G.B. John Mancini, MD, University of British Columbia, goes into detail about the recruitment process of the VICTORION-2-PREVENT trial, which focuses on inclisiran to reduce cardiovascular risk.
The VICTORION-2-PREVENT trial is taking place at the Gordon and Leslie Diamond Health Care Centre at the University of British Columbia and is currently in the recruiting process. The trial’s main objective is to provide evidence in favor of using inclisiran to lower cardiovascular risk in individuals who already have atherosclerotic cardiovascular disease (ASCVD) and elevated levels of low-density lipoprotein (LDL) cholesterol, despite being on a well-tolerated high-intensity statin therapy. Participants will be followed for 72 months.
G.B. John Mancini, MD, professor of medicine and director of the Cardiovascular Imaging Research Core Laboratory at the University of British Columbia, scientific director of the Cardio Risk Clinic, is the principal investigator (PI) of the VICTORION-2-PREVENT trial. Here, he details some of the criteria and recruiting process of the trial, and addresses the lack of women in CVD research and how he aims to avoid this issue in the trial.
Transcript
Can you tell us about the VICTORION-2-PREVENT trial involving inclisiran?
The VICTORION-2 trial is using the interesting technology of inclisiran, which is injected at baseline and then 3 months, and then after that it's only 2 injections a year, every 6 months. So, it's very attractive in that regard, in terms of the burden of injection, and it results in a sustained 50% lowering of LDL.
The trial is very exciting. It's in secondary prevention settings, so patients with prior MI [myocardial infarction] or stroke, or with symptomatic peripheral vascular disease. It's going to be huge—over 16,000 patients—and we've been recruiting well across Canada. The Canadian PIs are Drs [Liam] Brunham and [Shaun] Goodman. And we've had good success in getting our colleagues to support the recruitment of these kinds of patients who were on statins and their LDL is, in millimolar, above 1.8. That's about 80 in milligrams per deciliter. It's an outcome trial and event driven, so it'll be very impactful in terms of the ultimate utility of inclisiran for reducing cardiovascular risk.
What steps are you taking during recruitment to ensure a representative patient population that can be followed for all 72 months?
We have, in our setting, a group of very dedicated research nurses and research associates that scour all the patient records for us and engage all of the clinicians in our environment to encourage them to enroll appropriate patients, if the inclusion criteria are met, obviously. We particularly hope to have a good representation of women in this trial, as is often a limitation of many cardiovascular trials. Really, it's a full court press in terms of all of the patients that come through our clinics.
Why is it difficult to recruit women for CVD trials?
The overall risk for women, and therefore the presentation of numbers of patients, is a little bit lower for women, so there is a systematic reason for that. But beyond that, many women have different social pressures, and the ability to accommodate frequent visits or blood tests and so on may be quite different between the sexes. Those are a few of the reasons that come to mind as to why, traditionally, these cardiovascular trials have been dominated by men. We hope that's not the case. We've seen examples where it has not been the case, and we hope to emulate that as much as possible in all the trials we're doing.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Patient Navigation in Oncology at Heart of Priority Health White House Visit
April 24th 2024On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
Read More